Comparative dose titration responses to the introduction of bisoprolol or carvedilol in stable chronic systolic heart failure

Cardiovascular Drugs and Therapy

Volumn 21, Issue 6, 2007, Pages 437-444

  Hamaad, Ali ^a   Lip, Gregory Y H ^a   Nicholls, Deborah ^a   MacFadyen, Robert J ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Beta blockers; Bisoprolol; Carvedilol; Heart rate variability; Left ventricular systolic dysfunction

Indexed keywords

AMIODARONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SPIRONOLACTONE; VASODILATOR AGENT; WARFARIN;

AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HEART LEFT VENTRICLE FAILURE; HEART RATE; HEART RATE VARIABILITY; HUMAN; MALE; MORTALITY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HEART FAILURE; UNSPECIFIED SIDE EFFECT;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; BISOPROLOL; BLOOD PRESSURE; CARBAZOLES; CHRONIC DISEASE; FEMALE; HEART FAILURE, SYSTOLIC; HEART RATE; HUMANS; MALE; MIDDLE AGED; PROPANOLAMINES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 36849057573     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-007-6055-x     Document Type: Article

References (31)

1. MERIT-CHF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-CHF). Lancet 1999;353:2001-7.
2. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
3. Packer M, Coats AJS, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. New Eng J Med 2001;344:1651-8.
4. Bristow MR. β-adrenergic receptor blockade in chronic heart failure. Circulation 2000;101:558-69.
5. COMET Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13.
6. Dargie HJ. β-blockers in heart failure. The Lancet 2003;362:2-3.
7. Metra M, Torp-Pederson C, Swedberg K, on behalf of the COMET Trial Investigators, et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartate in patients with chronic heart failure: results from the COMET trial. Eur Heart J 2005;26:2259-68.
8. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Circulation 1996;93:1043-65.
9. Binder T, Frey B, Porenta G, et al. Prognostic value of heart rate variability in patients awaiting cardiac transplantation. PACE 1992;15:2215-20.
10. Brouwer J, van Veldhuisen DJ, Man in t'Veld, et al. Dutch Ibopamine Multicenter Trial Study Group. Prognostic value of heart rate variability during long-term follow-up in patients with mild to moderate heart failure. J Am Coll Cardiol 1996;29:1183-9.
11. Ponikowski P, Anker SD, Chua TP, et al. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure in secondary to ischaemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1997;79:1645-50.
12. Nolan J, Batin PD, Andrews R, et al. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 1998;98:1510-6.
13. Pousset F, Copie X, Lechat P, et al. Effects of Bisoprolol on heart rate variability in heart failure. Am J Cardiol 1996;77:612-7.
14. Aronson D, Burger AJ. Effect of beta-blockade on heart rate variability in decompensated heart failure. Int J Cardiol 2001;79:31-9.
15. Mortara A, La Rovere MT, Pinna GD, et al. Nonselective beta-adrenergic blocking agent carvedilol improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure. J Am Coll Cardiol 2000;36:1612-8.
16. Akdeniz B, Guneri S, Savas IZ, et al. Effects of carvedilol therapy on arrhythmia markers in patients with congestive heart failure. Int Heart J 2006;47:565-73.
17. Jansson K, Hagerman I, Ostlund R, et al. The effects of metoprolol and captopril on heart rate variability in patients with idiopathic dilated cardiomyopathy. Clin Cardiol 1999;22:397-402.
18. Goldsmith RL, Bigger JT, Bloomfield DM, et al. Long-term carvedilol therapy increases parasympathetic nervous system activity in chronic congestive heart failure. Am J Cardiol 1997;80:1101-4.
19. Copie X, Pousset F, Lechat P, et al. Effects of betablockade with bisoprolol on heart rate variability in advanced heart failure: analysis of scatterplots of R-R intervals at selected heart rates. Am Heart J 1996;132:369-75.
20. Niemela MJ, Airaksinen KE, Huikuri HV. Effect of beta-blockade on heart rate variability in patients with coronary disease. J Am Coll Cardiol 1994;23:1370-7.
21. Lurje L, Wennerblom B, Tygesen H, Karlsson T, Hjalmarson A. Heart rate variability after acute myocardial infarction in patients treated with atenolol and metoprolol. Int J Cardiol 1997;60:157-64.
22. Kardos A, Long V, Bryant J, Singh J, Sleight P, Casadei B. Lipophilic versus hydrophilic β1 blockers and the cardiac sympatho-vagal balance during stress and daily activity in patients after acute myocardial infarction. Heart 1998;79:153-60.
23. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 1996;93:1043-65.
24. Goyal D, MacFadyen RJ, Watson RD, Lip GYH. Ambulatory blood pressure monitoring in heart failure: a systematic review. Eur J heart Failure 2005;7:149-56.
25. Kindermann M, Maack C, Schaller S, et al. Carvedilol but not metoprolol reduces beta-adrenergic responsiveness after complete elimination from plasma in vivo. Circulation 2004;109:3182-90, Jun 29.
26. Sanderson JE, Chan SKW, Yip GY, et al. Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. J Am Coll Cardiol 1999;34:1522-8.
27. Malik M, Xia R, Odemuyiwa O, et al. Influence of the recognition of artefact in the autonomic analysis of long-term electrocardiograms on time-domain measurement of heart rate variability. Med Biol Eng Comput 1993;31:539-44.
28. Casadei B, Moon J, Johnston J, Caiazza A, Sleight P. Is respiratory sinus arrhythmia a good index of cardiac vagal tone in exercise? Am J Physiol 1996;81:556-64.
29. Mortara A, La Rovere MT, Signorini MG, et al. Can power spectral analysis of heart rate variability identify a high risk subgroup of congestive heart failure patients with excessive sympathetic activation? A pilot study before and after heart transplantation. Br Heart J 1994;71:422-30.
30. Van de Born P, Montano N, Pagani M, Oren R, Somers VK. Absence of low-frequency variability of sympathetic nerve activity in severe heart failure. Circulation 1997;95:1449-54.
31. Malik M, Hnatkova K, Camm AJ. Practicality of post infarction risk assessment based on time domain measurement of heart rate variability. Chapter 30 pp. 393-405 Heart Rate Variability 1995; Futura, Armonk NY